Dublin, Feb. 20, 2019 (GLOBE NEWSWIRE) -- The "Europe CGM Market, Users, Reimbursement Policy, Continuous Glucose Monitoring Components (Glucose Sensor, Transmitter), Diabetes (Type1 & 2) Population, & Forecast" report has been added to ResearchAndMarkets.com's offering.
Europe CGM Market is expected to surpass US$ 800 Million by the end of the year 2024
Good healthcare infrastructure, rising healthcare expenditure and awareness of patients regarding CGM technology in Europe will further accelerate the market of Continuous Glucose Monitoring (CGM) device. Continuous Glucose Monitoring (CGM) device are comparatively new innovation in diabetes management.
The conventional technique that permits users for one time check of glucose levels, but the CGM systems manage, monitor and inform the user if the glucose level nears current levels. The CGM system measures glucose from the tissues as compared to manual testing of blood by a finger-stick glucose meter assists in identifying glucose levels for a longer span of time.
Generally, people who suffer from diabetes develop poor habits over the years which gradually seem hard to break. Using CGM systems that assist to control the desired glucose level by well awareness and understanding of food intake and blood glucose trends after eating specific foods.
Germany & France CGM Market will remain a dominant force in the European Region
According to this market research report, Germany & France is expected to be a dominant force in Europe Continuous Glucose Monitoring (CGM) market. The adoption of CGM device is comparatively faster in Sweden compared to other European region. As per many diabetes experts, CGM is the compatible device for effective diabetes management for people having severe complications (hypoglycemia or hyperglycemia) in the day to day life.
European Countries Reimbursement Policies on CGM Device
This report provides complete assessment of CGM reimbursement for specific countries that include: United Kingdom, Germany, France, Sweden, Switzerland and Netherlands. Many countries provide CGM reimbursement to pediatric, gestational diabetes and type 1 diabetes patients only. It is anticipated that continuous glucose monitoring systems will be widely accessible to all diabetes patients whether it type 1 or type 2.
This latest study Europe CGM Market, Users, Reimbursement Policy, Continuous Glucose Monitoring Components (Glucose Sensor, Transmitter) Market, Diabetes (Type1 & 2) Population, & Forecast provides a detailed and comprehensive insight of the Europe CGM Market.
This report studies the Continuous Glucose Monitoring (CGM) market from 3 view points:
- CGM Market
- CGM Users
- CGM Reimbursements Policy
The scope of the Report:
- CGM Market & Forecast: We have defined the CGM market of 6 countries. Market data from 2010 to 2017 and Forecast from 2018 to 2024
- CGM Users & Forecast: We have defined CGM number of Users of 6 countries. Market data from 2010 to 2017 and Forecast from 2018 to 2024
- Reimbursement Policy: Report provides Reimbursement Policy on CGM for 6 countries individually along with global CGM (Continuous Glucose Monitoring) reimbursement model
- Diabetes Population: Report covers 6 Countries Type 1 and Type 2 Diabetes Population Numbers and Forecast
- Growth Factors for CGM: This topic studies the factor which is helping the CGM industry to grow.
- Challenges for CGM: This industry shows the problems being faced by the CGM technology
Key Topics Covered:
1. Executive Summary
2. Europe - CGM User (2010 - 2024)
3. Europe - CGM Market & Forecast (2010 - 2024)
4. By Components - CGM Market (2010 - 2024)
4.1 Glucose Sensor Market & Forecast
4.2 CGM Transmitter Market & Forecast
5. Market Share - By Countries
6. Reimbursement Model - Europe CGM (Continuous Glucose Monitoring)
7. Abbott Freestyle Libre vs CGM (Continuous Glucose Monitoring)
8. United Kingdom - Diabetes Population (2010 - 2024)
8.1 Total Diabetes Population
8.1.1 Type 1 Diabetes Population
8.1.2 Type 2 Diabetes Population
9. United Kingdom - CGM Market & Forecast
9.1 United Kingdom - CGM Market by Components
9.1.1 Glucose Sensor Market & Forecast
9.1.2 CGM Transmitter Market & Forecast
10. United Kingdom - CGM User (2010 - 2024)
11. CGM Reimbursement in United Kingdom
12. Germany - Diabetes Population (2010 - 2024)
12.1 Total Diabetes Population
12.1.1 Type 1 Diabetes Population
12.1.2 Type 2 Diabetes Population
13. Germany - CGM Market & Forecast
13.1 Germany - CGM Market by Components
13.1.1 Glucose Sensor Market & Forecast
13.1.2 CGM Transmitter Market & Forecast
14. Germany - CGM User (2010 - 2024)
15. CGM Reimbursement in Germany
16. Netherlands - Diabetes Population (2010 - 2024)
16.1 Total Diabetes Population
16.1.1 Type 1 Diabetes Population
16.1.2 Type 2 Diabetes Population
17. Netherlands - CGM Market & Forecast
17.1 Netherlands - CGM Market by Components
17.1.1 Glucose Sensor Market & Forecast
17.1.2 CGM Transmitter Market & Forecast
18. Netherlands - CGM User (2010 - 2024)
19. CGM Reimbursement in Netherlands
20. Sweden - Diabetes Population (2010 - 2024)
20.1 Total Diabetes Population & Forecast
20.1.1 Type 1 Diabetes Population
20.1.2 Type 2 Diabetes Population
21. Sweden - CGM Market & Forecast
21.1 Sweden - CGM Market by Components
21.1.1 Glucose Sensor Market & Forecast
21.1.2 CGM Transmitter Market & Forecast
22. Sweden - CGM User (2010 - 2024)
23. CGM Reimbursement in Sweden
24. France - Diabetes Population (2010 - 2024)
24.1 Diabetes Population
24.1.1 Type 1 Diabetes Population
24.1.2 Type 2 Diabetes Population
25. France - CGM Market & Forecast
25.1 France - CGM Market by Components
25.1.1 Glucose Sensor Market & Forecast
25.1.2 CGM Transmitter Market & Forecast
26. France - CGM User (2010 - 2024)
27. CGM Reimbursement in France
28. Switzerland - Diabetes Population (2010 - 2024)
28.1 Total Diabetes Population
28.1.1 Type 1 Diabetes Population
28.1.2 Type 2 Diabetes Population
29. Switzerland - CGM Market & Forecast
29.1 Switzerland - CGM Market by Components
29.1.1 Glucose Sensor Market & Forecast
29.1.2 CGM Transmitter Market & Forecast
30. Switzerland - CGM User (2010 - 2024)
31. CGM Reimbursement in Switzerland
32. Growth Drivers
32.1 Continuous Positive Cost Effective Analysis by Several Countries
32.2 CGM Technology Convenient for both Patients & Physicians
33. Challenges
33.1 Controversy regarding Clinical Benefits
For more information about this report visit https://www.researchandmarkets.com/research/crnqrs/europe_cgm_market?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.